Core Insights - Korro Bio, Inc. has initiated dosing in its REWRITE study for KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD) [1][2] - The REWRITE study aims to evaluate the safety and tolerability of KRRO-110 in up to 64 participants, with interim data expected in the second half of 2025 [2][7] - KRRO-110 is designed to restore therapeutic M-AAT protein levels by utilizing the body's endogenous ADAR enzyme, with a focus on both lung and liver manifestations of AATD [2][5] Company Overview - Korro is a clinical-stage biopharmaceutical company focused on developing genetic medicines using its proprietary RNA editing platform, OPERA™ [6][8] - The company is transitioning from a research organization to a clinical-stage drug development entity, with plans to advance three product candidates into the clinic by 2027 [4][6] - Korro's approach aims to enhance the precision and tunability of genetic medicines by editing RNA instead of DNA, potentially improving long-term tolerability [6][8] Product Development - KRRO-110 is the first product candidate from Korro's RNA editing platform, targeting the genetic disorder AATD caused by a mutation in the SERPINA1 gene [5][7] - The REWRITE study consists of two parts: single and multiple dose-escalating studies, with secondary endpoints focusing on pharmacokinetic and pharmacodynamic parameters [2][4] - The company is also advancing additional pipeline programs, including a partnership with Novo Nordisk in a cardiometabolic indication [3][4]

Company Overview - Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases [3] - The company utilizes a proprietary RNA editing platform to create a portfolio of differentiated programs that enable precise yet transient single base edits [3] - By editing RNA instead of DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to increased specificity and improved long-term tolerability [3] Upcoming Events - Ram Aiyar, Ph.D., CEO and President of Korro, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 3:45 p.m. PT [1] - Vineet Agarwal, CFO, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in the conference [1] - A live webcast of the presentation will be available on Korro's website, with a replay accessible for 30 days following the event [2]

Company Overview - Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and prevalent diseases [4] - The company utilizes a proprietary RNA editing platform to create a portfolio of differentiated programs aimed at precise and transient single base edits [4] - By editing RNA instead of DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to improved specificity and long-term tolerability [4] Upcoming Events - Management will participate in several investor conferences, including: - Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, featuring a fireside chat with CEO Ram Aiyar [1] - 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024, with another fireside chat by Dr. Aiyar [2] - Citi's 2024 Global Healthcare Conference on December 5, 2024, with 1x1 investor meetings [2] - Oppenheimer Movers in Rare Disease Summit on December 12, 2024, where Dr. Aiyar will participate in a panel discussion [3] Access to Presentations - Live webcasts of the fireside chats at the Piper Sandler and Evercore conferences will be available on Korro's website, with replays accessible for 30 days post-event [3]

Core Insights - Korro Bio, Inc. has received approval to initiate a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) in Australia [1][2] - The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KRRO-110, with the first participant dosing expected in Q1 2025 and completion anticipated in 2026 [1][4] Company Overview - Korro Bio is focused on developing a new class of genetic medicines using its proprietary RNA editing platform, OPERA™, targeting both rare and prevalent diseases [6][7] - KRRO-110 is the first RNA editing oligonucleotide candidate from Korro, designed to edit the SERPINA1 RNA to restore normal AAT protein secretion [6] Study Details - The REWRITE study will involve up to 64 participants, including healthy adults and clinically stable AATD patients with the PiZZ genotype [3] - Secondary and exploratory endpoints will include pharmacokinetic and pharmacodynamic parameters to guide optimal dose selection for future studies [3] Clinical Expectations - Interim readout for the study is expected in the second half of 2025, focusing on participants with the PiZZ genotype [4] - The study's design aims to demonstrate the potential of KRRO-110 in patients at risk for serious lung and liver complications despite standard treatment [2][9]

Company Overview - Korro Bio, Inc. is a biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases [3] - The company utilizes a proprietary RNA editing platform to create a portfolio of differentiated programs aimed at achieving precise and transient single base edits [3] - By editing RNA instead of DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to increased specificity and improved long-term tolerability [3] Upcoming Events - Ram Aiyar, Ph.D., CEO and President of Korro, will present at the Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. GMT [1] - Vineet Agarwal, CFO, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in the conference [1] - A live webcast of the presentation will be available on Korro's website, with a replay accessible for 30 days following the event [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | --- | --- | --- | |---------------------------|-----------|-------------------------------------------------------| | | | | | | Trading | | | Title of each class | Symbol(s) | Name of each exchange on which registered | FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Exhibit 99.1 Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates — Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) — Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team — Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform — Ended third quarter of 2024 with $169.1 mil ...

-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 -First participant dosing anticipated in first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2 study anticipated in 2026 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), ...

Shares of Korro Bio, Inc. (KRRO) have gained 6.7% over the past four weeks to close the last trading session at $39.76, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $135 indicates a potential upside of 239.5%. The mean estimate comprises five short-term price targets with a standard deviation of $42.13. While the lowest estimate of $95 indicates a 138.9% increase from the cur ...

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024. Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral ...